On October 20, 2025, Genomic Medicine Sweden (GMS) announced the launch of five strategic development projects aimed at extending access to advanced diagnostics nationwide. The projects will focus on updating national GMS gene panel (big NGS panel for solid tumors), liquid biopsies, cell-free tumor DNA (ctDNA) for diagnosis and follow-up of metastatic breast cancer, gene panels for hepatopancreatobiliary (HPB) cancer, and improving diagnosis of sarcoma.

On October 17, 2025, the European Commission adopted an implementing regulation that sets detailed procedural rules for Joint Clinical Assessments of medical devices and in vitro diagnostics under the HTA Regulation, which entered into force on 12 January 2025.

The MTRC team, including Director Oleg Borisenko and Deputy Reimbursement Lead Julia Mazur, will be attending the ISPOR meeting in Glasgow, Scotland on 9-12 November.

In October 2025, the Norwegian Directorate of Health released a preliminary version of the DRG system (Innsatsstyrt finansiering, ISF) for 2026. In general, no significant changes were made in the system. Two new DRGs will be added in 2026 concerning cell therapy and radiotherapy.

On October 16, 2025, the Federal Joint Committee (G-BA) launched the consultation procedure on a risk-adapted prostate-specific antigen (PSA) and MRI-based screening for the early detection of prostate cancer, in line with §135 SGB V (G-BA Directive on Ambulatory Care Methods; conceptually new diagnostic and therapeutic methods). Public comments may be submitted electronically by November 23, 2025.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of October 20th, we plan to work on 21 projects. Review the complete list of planned activities in this post.

On October 18, 2025, the Decision of the National Union of Health Insurance Funds (UNCAM) on the update of the list of procedures and services covered by the Health Insurance, including the CCAM Classification, was published. The updates do not include new codes and concern adjustments of tariffs and billing rules for conventional radiology procedures. The Decision also implements the update of technical packages for CT scanners, MRIs, and PET scans set by the Medical Convention.

MTRC has released a White Paper titled "Evidence requirements for medical devices in the “New methods” framework in Norway”. This White Paper provides an opportunity to learn about the evidence requirements related to the 'New Methods' framework from the 5 recent med tech assessments in Norway. The review is followed by recommendations on evidence generation and will be useful for medical device manufacturers seeking market access in Norway, as well as HTA professionals and policymakers interested in the Norwegian evaluation framework.

As of October 2025, the Dutch Healthcare Institute (ZIN) is working on coverage positions in several areas, including otorhinolaryngology, neurology, dental surgery, cardiovascular, and oncology fields.

On October 14, 2025, it was announced that the decree from the Ministry of Health for the National HTA Program for Medical Devices (PNHTA-DM) 2026–2028 has been submitted to the State–Regions Conference opinion. The Program was developed by the National Agency for Regional Health Services (AGENAS) and approved by the HTA Steering Committee.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, Scandurra et al. evaluated the ecological footprint of anesthesia by analyzing sevoflurane consumption and anesthesiologists’ awareness of its environmental impact across Belgium, France, and Italy.

MTRC, a leading boutique Med Tech Market Access and HEOR consultancy in Europe, is looking for a Junior Health Economist.